Pimavanserin tartrate

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms, leaving millions with conditions that traditional pharma cannot cure. New FDA guidances from October 2025 outline streamlined approval pathways for cell and gene therapies targeting severe conditions in small populations[1], signaling regulatory momentum toward advanced platforms that replace, repair, or modify disease-causing genes rather than simply managing symptoms. These companies represent a new generation of biotechs pursuing targeted solutions where traditional drugs have reached their limits: Avant Technologies, Inc. (OTCQB: AVAI), Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Moleculin Biotech, Inc. (NASDAQ: MBRX), Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), and Fractyl Health, Inc. (NASDAQ: GUTS). According to Precedence Research, the precision medicine market reached $118.52 billion in 2025 and analysts project growth to $463.11 billion by 2034[2], driven by breakthroughs in gene editing technologies and personalized therapeutic approaches that match treatments to individual genetic profiles. October 2025 saw multiple gene therapies receive platform technology designations and rare disease pathway selections from the FDA[3], reflecting regulatory priorities that favor companies developing durable, one-time treatments for high-unmet-need populations including rare genetic disorders, neurodegenerative diseases, and treatment-resistant cancers. Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic transformation toward a partnership-driven business model that could position the company at the intersection of disease detection and advanced cell-based therapeutics. Through strategic joint ventures, Avant appears to be building what may become an integrated healthcare platform, identifying genetically modified cell lines to address hard to treat diseases while developing targeted cell-based treatments through innovative biotechnology partnerships. Back in June 2025, Avant announced plans to create a new company to house a joint venture, partnership, or acquisition as it explores expanding its interests in a diabetes development program offering potential treatment opportunities. Chris Winter, CEO of Avant, said, "We are exploring several promising opportunities to get involved in the development of a treatment for diabetes globally." Avant's most clinically advanced partnership, Klothonova, Inc., is a 50/50 joint venture with Singapore-based cell therapy pioneer Austrianova that demonstrates the company's treatment development capabilities. Klothonova focuses on developing cell-based therapies utilizing encapsulated Klotho-producing cells targeting age-related diseases while also developing anti-aging therapies for the promotion of longevity and quality of life. The program successfully completed its initial R&D proof of concept phase, where Austrianova generated genetically modified human cells that over-produce the Klotho protein. These cells were successfully encapsulated in Austrianova's proprietary Cell-in-a-Box® technology and shown to produce the Klotho protein continuously, demonstrating the feasibility of this approach. The program is now advancing to GMP-grade production for potential preclinical and clinical studies, with preparations underway at Austrianova's ISO9001:2015 compliant facility. "The R&D level proof of concept study provides a clear rationale for the program, giving a green light to move to GMP studies," said Winter. "By prioritizing GMP compliance from the outset, Klothonova is committed to delivering safe, effective treatments that could transform the landscape of age-related disease management." The scientific foundation for Klotho-based therapies appears compelling. Studies show higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lower Klotho levels had 31% higher mortality rates. Critically, natural Klotho levels drop by 50% after age 40, potentially creating substantial therapeutic opportunities for this "longevity protein" that affects brain, heart, kidney, and immune function. Austrianova's cell-encapsulation platform is backed by over 50 peer-reviewed publications and 30+ years of development. The technology represents an approach that has been studied for multiple therapeutic protein applications. While Avant has not disclosed specific details about which approaches it may pursue for its diabetes treatment exploration, the company's partnerships demonstrate capabilities in both disease detection and cell-based therapeutic development. The potential market opportunity spans multiple therapeutic areas. The global Alzheimer's market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. The cell-based therapy market could reach $44 billion globally. "Our transition to a partnership-driven model represents a transformative step for Avant," said Winter. "By combining forces with top-tier experts, we're not just identifying diseases. We're actively developing solutions that could change lives." CONTINUED... Read this and more news for Avant Technologies at: Lexeo Therapeutics, Inc. (NASDAQ: LXEO) has achieved significant progress toward an accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy, with the FDA indicating openness to pooling data from ongoing Phase I/II studies with pivotal trial data to support a Biologics License Application. Participants with abnormal baseline left ventricular mass index achieved a 23% mean reduction at 12 months, exceeding the FDA-aligned target threshold of 10%. Interim data from 16 participants showed sustained improvements across both cardiac and neurologic measures, with 14 of 16 participants achieving over 25% reduction in high-sensitivity troponin I and clinically meaningful improvement in the modified Friedreich Ataxia Rating Scale. "We are encouraged by our recent dialogue with the FDA on LX2006, and we appreciate the Agency's collaborative spirit as we work to deliver a potentially life-changing therapy to the FA community as efficiently as possible," said R. Nolan Townsend, CEO of Lexeo Therapeutics. "Given the highly compelling data to date that demonstrate clinically meaningful improvements across both cardiac and neurologic measures of FA, we are now pursuing a development strategy that could enable a smaller pivotal study, given the potential to pool data with the ongoing Phase I/II trials, as well as potentially assessing the co-primary endpoint of LVMI earlier than 12 months." The company plans to initiate the LX2006 pivotal study in the first half of 2026 pending protocol finalization, with LX2006 having received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations from the FDA. Treatment with LX2006 has been generally well tolerated with no Grade 3+ serious adverse events to date across 17 participants. Moleculin Biotech, Inc. (NASDAQ: MBRX) has secured a notice of allowance from the Canadian Intellectual Property Office for Patent Application No. 3,142,510 covering methods of making preliposomal Annamycin lyophilizate with improved stability and high purity. The patent claims extend until June 2040, subject to extension for regulatory approval timelines, strengthening the company's intellectual property portfolio for its lead anthracycline candidate Annamycin being developed for acute myeloid leukemia and soft tissue sarcoma lung metastases. This Canadian patent complements previously issued U.S. and allowed European patents, with additional applications pending in major jurisdictions worldwide. "We remain committed to bolstering our global intellectual property portfolio for Annamycin," said Walter Klemp, Chairman and CEO of Moleculin. "This Canadian patent further strengthens our current IP portfolio which includes claims to methods of making our preliposomal Annamycin, in yet another key territory." Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML, plus Orphan Drug Designation for soft tissue sarcoma lung metastases from both the FDA and EMA. The company has begun the MIRACLE Trial (MB-108), a pivotal Phase 3 adaptive design study evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia, positioning the candidate as potentially the first non-cardiotoxic anthracycline to receive regulatory approval. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is presenting clinical data across multiple therapeutic programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders, including a late-breaker oral platform presentation on ACP-711, an investigational GABAA subunit α3 selective modulator under development for essential tremor. The company is showcasing preclinical efficacy, safety, and mechanism of action findings on ACP-711, alongside presenting the Phase 2 study design for ACP-204 in adults with Lewy body dementia psychosis and encore findings from post-hoc analysis evaluating duration of illness and response to NUPLAZID (pimavanserin) in Parkinson's disease psychosis. NUPLAZID, approved by the FDA in April 2016, is a selective serotonin inverse agonist targeting 5-HT2A receptors for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company's robust pipeline demonstrates progress beyond NUPLAZID, with ACP-204 representing a novel 5-HT2A inverse agonist/antagonist advancing through mid-stage development for Lewy body dementia psychosis. Acadia's portfolio reflects commitment to underserved neurological disease communities, developing therapeutic advancements with programs in Alzheimer's disease psychosis and other neuropsychiatric conditions affecting patients with limited treatment options. Fractyl Health, Inc. (NASDAQ: GUTS) announced potent preclinical results from RJVA-002, a dual GIP/GLP-1 gene therapy candidate for obesity, with data showing approximately 30% weight loss at five weeks in a diet-induced obesity mouse model, with the weight loss trajectory not yet plateaued. The single administration of RJVA-002 led to dose-dependent reductions in body weight, with mid-dose and high-dose cohorts achieving 18% and 29% mean weight loss respectively by day 35, with no adverse effects observed in treated animals. These translational results suggest RJVA-002 has potential to match or exceed best-in-class chronic drug therapy from a single point-in-time treatment, expanding the company's Rejuva Smart GLP-1 platform from durable treatment of type 2 diabetes to obesity. "These RJVA-002 data further support our Smart GLP-1 gene therapy platform approach and suggest that dual gut hormone expression has the potential to produce powerful metabolic effects," said Harith Rajagopalan, M.D., Ph.D., Co-Founder and CEO of Fractyl Health. "Together with the recently reported REMAIN-1 data, and with RJVA-001 nearing the clinic in 2026, these results underscore the strength and breadth of our portfolio." The company is advancing a multi-modality strategy with RJVA-001 expected to enter first-in-human clinical trials in 2026 for patients with inadequately controlled type 2 diabetes, while RJVA-002 targets dual incretin biology with the goal of achieving durable, well-tolerated weight loss from a single intervention. Fractyl has submitted the first Clinical Trial Application module for RJVA-001 to regulators and has a robust intellectual property portfolio with 33 granted U.S. patents and approximately 40 pending U.S. applications. Source: need-to-know/ CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: 1. 2. 3. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint. The safety and tolerability profile of intranasal carbetocin was consistent with previous clinical trials, showing a low rate of adverse events. “We are disappointed by these findings, especially for Prader-Willi syndrome patients, their families and the entire community,” said Elizabeth H.Z. Thompson, Ph.D., Acadia’s Head of Research and Development. “I want to thank the many patients, families, study site personnel, and physicians who participated in the COMPASS PWS study as well as the intranasal carbetocin clinical development program, for their dedication and contributions in this important study. We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further.” COMPASS PWS was a 12-week, double-blind, randomized, placebo-controlled global Phase 3 trial evaluating the efficacy and safety of intranasal carbetocin 3.2 mg three times daily (TID) in 175 enrolled children and adults aged five to 30 years with PWS. “Despite this disappointment, Acadia is well-positioned to deliver long-term, sustainable growth supported by two approved products projected to generate over $1 billion in net sales in 2025, and a robust pipeline that includes eight disclosed and multiple undisclosed programs,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027. For more details on our programs, I encourage you to revisit our recent R&D Day presentation on our website.” About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Alzheimer’s disease psychosis, Lewy Body Demetia psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at acadia.com and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “intends,” “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: our clinical development plans related to intranasal carbetocin (ACP-101); our plans to share a summary of the data in the future; the safety and tolerability of intranasal carbetocin; our estimates regarding our future financial performance, including our full year 2025 financial guidance; and our business strategy, objectives and opportunities, including the timing for and clinical and market potential of our pipeline assets, and potential for enhanced shareholder value. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties, assumptions and other factors include, but are not limited to: our dependency on the continued successful commercialization of NUPLAZID and DAYBUE and our ability to maintain or increase sales of NUPLAZID or DAYBUE; our ability to generate or obtain the necessary capital to fund our clinical development plans; the risks associated with clinical trials and their outcomes, including risks of negative or inconsistent results; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ, please refer to our quarterly report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission on August 7, 2025, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.